{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Pancreatic+Neoplasm&page=6", "query": { "condition": "Malignant Pancreatic Neoplasm", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 213, "total_pages": 22, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Pancreatic+Neoplasm&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Pancreatic+Neoplasm&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T05:00:33.607Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05086692", "title": "A Beta-only IL-2 ImmunoTherapY Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Unresectable Solid Tumor", "Clear Cell Renal Cell Carcinoma", "Triple Negative Breast Cancer", "Non-Small Cell Lung Cancer Squamous", "Non-Small Cell Lung Cancer Non-squamous", "Colorectal Cancer (MSI-H)", "Gastric Cancer", "Cervical Cancer", "Basal Cell Carcinoma", "Bladder Cancer", "Merkel Cell Carcinoma", "Squamous Cell Carcinoma of Head and Neck", "Cutaneous Squamous Cell Carcinoma", "Pleural Mesothelioma", "Esophageal Cancer", "Endometrial Carcinoma", "Solid Tumor", "Solid Tumor, Adult", "MSI-H Solid Malignant Tumor", "Cancer With A High Tumor Mutational Burden", "Epithelial Ovarian Carcinoma", "Primary Peritoneal Cancer", "Gastroesophageal Junction (GEJ) Cancer", "Acral Melanoma", "Mucosal Melanoma", "Cutaneous Melanoma", "DMMR Solid Malignant Tumor", "Fallopian Tube Cancer", "Ovarian Cancer", "MSI-H Cancer", "DMMR Cancer", "Pancreas Adenocarcinoma (MSI-H)", "Skin Cancer", "Viral Cancer", "Cervical Cancers", "Endometrial Cancer" ], "interventions": [ { "name": "MDNA11", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medicenna Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2021-08-27", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2025-07-09", "last_synced_at": "2026-10-13T05:00:33.607Z", "location_count": 7, "location_summary": "San Diego, California • San Francisco, California • Santa Monica, California + 4 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05086692" }, { "nct_id": "NCT00028496", "title": "Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma of the Colon", "Adenocarcinoma of the Gallbladder", "Adenocarcinoma of the Pancreas", "Adenocarcinoma of the Rectum", "Adult Primary Hepatocellular Carcinoma", "Advanced Adult Primary Liver Cancer", "Cholangiocarcinoma of the Gallbladder", "Diffuse Adenocarcinoma of the Stomach", "Intestinal Adenocarcinoma of the Stomach", "Male Breast Cancer", "Mixed Adenocarcinoma of the Stomach", "Ovarian Endometrioid Adenocarcinoma", "Paget Disease of the Breast With Intraductal Carcinoma", "Paget Disease of the Breast With Invasive Ductal Carcinoma", "Recurrent Adult Primary Liver Cancer", "Recurrent Breast Cancer", "Recurrent Colon Cancer", "Recurrent Gallbladder Cancer", "Recurrent Gastric Cancer", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Pancreatic Cancer", "Recurrent Rectal Cancer", "Recurrent Salivary Gland Cancer", "Salivary Gland Adenocarcinoma", "Stage II Malignant Testicular Germ Cell Tumor", "Stage II Pancreatic Cancer", "Stage III Colon Cancer", "Stage III Gastric Cancer", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Pancreatic Cancer", "Stage III Rectal Cancer", "Stage III Salivary Gland Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Gastric Cancer", "Stage IV Pancreatic Cancer", "Stage IV Rectal Cancer", "Stage IV Salivary Gland Cancer", "Thyroid Gland Medullary Carcinoma", "Unresectable Gallbladder Cancer" ], "interventions": [ { "name": "recombinant fowlpox-CEA(6D)/TRICOM vaccine", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "recombinant fowlpox GM-CSF vaccine adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2001-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-25", "last_synced_at": "2026-10-13T05:00:33.607Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00028496" }, { "nct_id": "NCT00711191", "title": "A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Neoplasm" ], "interventions": [ { "name": "monoclonal antibody", "type": "BIOLOGICAL" }, { "name": "chemotherapy", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2008-06", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2013-12-24", "last_synced_at": "2026-10-13T05:00:33.607Z", "location_count": 2, "location_summary": "Indianapolis, Indiana • Philadelphia, Pennsylvania", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00711191" }, { "nct_id": "NCT00006981", "title": "Immunotoxin Therapy in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cervical Cancer", "Fallopian Tube Cancer", "Head and Neck Cancer", "Lung Cancer", "Malignant Mesothelioma", "Ovarian Cancer", "Pancreatic Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "SS1(dsFv)-PE38 immunotoxin", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-30", "last_synced_at": "2026-10-13T05:00:33.607Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006981" }, { "nct_id": "NCT02451553", "title": "Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Bile Duct Carcinoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Pancreatic Carcinoma", "Stage III Pancreatic Cancer AJCC v6 and v7", "Stage IVA Pancreatic Cancer", "Stage IVB Pancreatic Cancer" ], "interventions": [ { "name": "Afatinib Dimaleate", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 41, "start_date": "2015-11-05", "completion_date": "2022-04-16", "has_results": false, "last_update_posted_date": "2022-06-07", "last_synced_at": "2026-10-13T05:00:33.607Z", "location_count": 2, "location_summary": "Indianapolis, Indiana • Seattle, Washington", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02451553" }, { "nct_id": "NCT01365169", "title": "Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients\"", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Malignant Head and Neck Neoplasm", "Malignant Neoplasm", "Metastatic Malignant Neoplasm in the Neck", "Metastatic Malignant Neoplasm in the Uterine Cervix", "Pancreatic Adenocarcinoma", "Pancreatic Neuroendocrine Carcinoma", "Recurrent Colorectal Carcinoma", "Stage I Colorectal Cancer AJCC v6 and v7", "Stage I Hypopharyngeal Carcinoma AJCC v7", "Stage I Major Salivary Gland Cancer AJCC v7", "Stage I Nasopharyngeal Carcinoma AJCC v7", "Stage I Oral Cavity Cancer AJCC v6 and v7", "Stage I Oropharyngeal Carcinoma AJCC v6 and v7", "Stage II Colorectal Cancer AJCC v7", "Stage II Hypopharyngeal Carcinoma AJCC v6 and v7", "Stage II Major Salivary Gland Cancer AJCC v7", "Stage II Nasopharyngeal Carcinoma AJCC v7", "Stage II Oral Cavity Cancer AJCC v6 and v7", "Stage II Oropharyngeal Carcinoma AJCC v6 and v7", "Stage IIA Colorectal Cancer AJCC v7", "Stage IIB Colorectal Cancer AJCC v7", "Stage IIC Colorectal Cancer AJCC v7", "Stage III Colorectal Cancer AJCC v7", "Stage III Hypopharyngeal Carcinoma AJCC v7", "Stage III Laryngeal Cancer AJCC v6 and v7", "Stage III Major Salivary Gland Cancer AJCC v7", "Stage III Nasopharyngeal Carcinoma AJCC v7", "Stage III Oral Cavity Cancer AJCC v6 and v7", "Stage III Oropharyngeal Carcinoma AJCC v7", "Stage IIIA Colorectal Cancer AJCC v7", "Stage IIIB Colorectal Cancer AJCC v7", "Stage IIIC Colorectal Cancer AJCC v7", "Stage IV Colorectal Cancer AJCC v7", "Stage IVA Colorectal Cancer AJCC v7", "Stage IVA Hypopharyngeal Carcinoma AJCC v7", "Stage IVA Laryngeal Cancer AJCC v7", "Stage IVA Major Salivary Gland Cancer AJCC v7", "Stage IVA Nasopharyngeal Carcinoma AJCC v7", "Stage IVA Oral Cavity Cancer AJCC v6 and v7", "Stage IVA Oropharyngeal Carcinoma AJCC v7", "Stage IVB Colorectal Cancer AJCC v7", "Stage IVB Hypopharyngeal Carcinoma AJCC v7", "Stage IVB Laryngeal Cancer AJCC v7", "Stage IVB Major Salivary Gland Cancer AJCC v7", "Stage IVB Nasopharyngeal Carcinoma AJCC v7", "Stage IVB Oral Cavity Cancer AJCC v6 and v7", "Stage IVB Oropharyngeal Carcinoma AJCC v7", "Metastatic or Locally Unresectable Solid Tumor" ], "interventions": [ { "name": "Exercise Intervention", "type": "BEHAVIORAL" }, { "name": "Health Telemonitoring", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 590, "start_date": "2011-05-25", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-10-13T05:00:33.607Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01365169" }, { "nct_id": "NCT00003923", "title": "Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extrahepatic Bile Duct Cancer", "Gallbladder Cancer", "Liver Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "porfimer sodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "1999-03", "completion_date": "2002-02", "has_results": false, "last_update_posted_date": "2013-03-04", "last_synced_at": "2026-10-13T05:00:33.607Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003923" }, { "nct_id": "NCT00267020", "title": "Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Neoplasm" ], "interventions": [ { "name": "enzastaurin", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2005-12", "completion_date": "2008-05", "has_results": true, "last_update_posted_date": "2020-08-31", "last_synced_at": "2026-10-13T05:00:33.607Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00267020" }, { "nct_id": "NCT00030498", "title": "Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Anaplastic Astrocytoma", "Adult Anaplastic Ependymoma", "Adult Anaplastic Oligodendroglioma", "Adult Brain Stem Glioma", "Adult Diffuse Astrocytoma", "Adult Ependymoblastoma", "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Adult Mixed Glioma", "Adult Myxopapillary Ependymoma", "Adult Oligodendroglioma", "Adult Pilocytic Astrocytoma", "Adult Primary Hepatocellular Carcinoma", "Adult Subependymoma", "Advanced Adult Primary Liver Cancer", "Advanced Malignant Mesothelioma", "Male Breast Cancer", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Adult Brain Tumor", "Recurrent Adult Primary Liver Cancer", "Recurrent Anal Cancer", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Bladder Cancer", "Recurrent Breast Cancer", "Recurrent Cervical Cancer", "Recurrent Colon Cancer", "Recurrent Esophageal Cancer", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Malignant Mesothelioma", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Pancreatic Cancer", "Recurrent Prostate Cancer", "Recurrent Rectal Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Stage II Esophageal Cancer", "Stage II Pancreatic Cancer", "Stage III Esophageal Cancer", "Stage III Pancreatic Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Anal Cancer", "Stage IV Basal Cell Carcinoma of the Lip", "Stage IV Bladder Cancer", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Esophageal Cancer", "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Lymphoepithelioma of the Oropharynx", "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Pancreatic Cancer", "Stage IV Prostate Cancer", "Stage IV Rectal Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity", "Stage IVA Cervical Cancer", "Stage IVB Cervical Cancer", "Unspecified Adult Solid Tumor, Protocol Specific", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2001-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-16", "last_synced_at": "2026-10-13T05:00:33.607Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00030498" }, { "nct_id": "NCT03752398", "title": "A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma (Excluding Uveal Melanoma)", "Cervical Carcinoma", "Pancreatic Carcinoma", "Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative", "Hepatocellular Carcinoma", "Urothelial Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Nasopharyngeal Carcinoma", "Renal Cell Carcinoma", "Colorectal Carcinoma", "Endometrial Carcinoma", "Non-small Cell Lung Carcinoma", "Small Cell Lung Cancer", "Gastric or Gastroesophageal Junction Adenocarcinoma", "Advanced Solid Tumors", "Undifferentiated Pleomorphic Sarcoma" ], "interventions": [ { "name": "XmAb®23104", "type": "BIOLOGICAL" }, { "name": "Yervoy® (ipilimumab)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 198, "start_date": "2019-05-01", "completion_date": "2024-02-15", "has_results": false, "last_update_posted_date": "2024-07-05", "last_synced_at": "2026-10-13T05:00:33.607Z", "location_count": 18, "location_summary": "San Diego, California • Aurora, Colorado • Denver, Colorado + 15 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03752398" } ] }